Suppr超能文献

连续7天每天一次经阴道给予[14C]达匹韦林凝胶制剂后,恒河猴和兔体内达匹韦林的浓度。

Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14C]dapivirine for 7 days.

作者信息

Nuttall Jeremy P, Thake Daryl C, Lewis Mark G, Ferkany John W, Romano Joseph W, Mitchnick Mark A

机构信息

International Partnership for Microbicides, 8401 Colesville Road, Suite 200, Silver Spring, MD 20910, USA.

出版信息

Antimicrob Agents Chemother. 2008 Mar;52(3):909-14. doi: 10.1128/AAC.00330-07. Epub 2007 Dec 17.

Abstract

Dapivirine is a nonnucleoside reverse transcriptase inhibitor being developed as a topical microbicide for the prevention of human immunodeficiency virus infection. The distribution of radioactivity and drug in plasma and in vaginal, cervical, and draining lymph node tissues was investigated after daily application of a vaginal gel formulation of [14C]dapivirine to rhesus macaques. This was preceded by a preliminary study with rabbits. Following the intravaginal administration of [14C]dapivirine ( approximately 0.1 mg/ml [15 microCi/ml]) to rabbits (0.5 ml/day) and macaques (1 ml/day) for 7 days, the dapivirine levels associated with vaginal and cervical tissue samples 1 h after the final dose were high (quantities of microg/g of tissue) and remained detectable at 24 h (mean, >or=2.5 ng/g in rabbits) and 48 h (mean, >80 ng/g in macaques). Radioactivity levels were low in the plasma and very low or unquantifiable in the draining lymph nodes of the macaques. Microautoradiography identified drug-related material (DRM) on the surfaces of the vaginal and cervical tissues of the rabbits and macaques. Although DRM was primarily associated with the outermost layer of shedding cells in rabbits, two animals showed some evidence of small quantities in the mucosal epithelium of the cervix. In macaques, DRM was seen within the keratinized layer of the vaginal epithelium and and was found to extend into the superficial cellular layers, and in at least one animal it appeared to be present in the deepest (germinal) layer of the epithelium and in submucosal tissues. The persistence of biologically significant concentrations of dapivirine in vaginal and cervical tissues for >24 h supports the development of dapivirine as a microbicide for once daily application.

摘要

达匹韦林是一种非核苷类逆转录酶抑制剂,正被开发用作预防人类免疫缺陷病毒感染的局部杀菌剂。在恒河猴每日应用[14C]达匹韦林阴道凝胶制剂后,研究了放射性和药物在血浆以及阴道、宫颈和引流淋巴结组织中的分布情况。在此之前,先对兔子进行了一项初步研究。给兔子(0.5毫升/天)和恒河猴(1毫升/天)阴道内给予[14C]达匹韦林(约0.1毫克/毫升[15微居里/毫升]),持续7天,最终剂量后1小时,与阴道和宫颈组织样本相关的达匹韦林水平很高(微克/克组织量),在24小时(兔子中平均≥2.5纳克/克)和48小时(恒河猴中平均>80纳克/克)仍可检测到。恒河猴血浆中的放射性水平较低,引流淋巴结中的放射性水平非常低或无法定量。显微放射自显影术在兔子和恒河猴的阴道和宫颈组织表面鉴定出了药物相关物质(DRM)。虽然DRM主要与兔子脱落细胞的最外层相关,但有两只动物的宫颈黏膜上皮有少量存在的迹象。在恒河猴中,DRM见于阴道上皮的角质化层内,并延伸至浅表细胞层,在至少一只动物中,它似乎存在于上皮的最深(生发)层和黏膜下组织中。达匹韦林在阴道和宫颈组织中具有生物学意义的浓度持续>24小时,这支持了将达匹韦林开发为每日应用一次的杀菌剂。

相似文献

3
A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film.
J Acquir Immune Defic Syndr. 2016 Apr 15;71(5):498-505. doi: 10.1097/QAI.0000000000000897.
4
Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B).
AIDS Res Hum Retroviruses. 2017 Apr;33(4):339-346. doi: 10.1089/AID.2016.0040. Epub 2016 Dec 13.
6
Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women.
AIDS Res Hum Retroviruses. 2010 Nov;26(11):1181-90. doi: 10.1089/aid.2009.0227. Epub 2010 Sep 21.
7
The sheep as a model of preclinical safety and pharmacokinetic evaluations of candidate microbicides.
Antimicrob Agents Chemother. 2015 Jul;59(7):3761-70. doi: 10.1128/AAC.04954-14. Epub 2015 Apr 6.
9
Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women.
J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):416-23. doi: 10.1097/qai.0b013e3181acb536.
10
Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir.
J Antimicrob Chemother. 2014 Sep;69(9):2477-88. doi: 10.1093/jac/dku160. Epub 2014 May 26.

引用本文的文献

1
HIV Pre-Exposure Prophylaxis: New and Upcoming Drugs to Address the HIV Epidemic.
Drugs. 2023 Dec;83(18):1677-1698. doi: 10.1007/s40265-023-01963-9. Epub 2023 Dec 11.
2
Baseline and time-updated factors in preclinical development of anionic dendrimers as successful anti-HIV-1 vaginal microbicides.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022 May;14(3):e1774. doi: 10.1002/wnan.1774. Epub 2022 Jan 12.
3
Physiologically-based pharmacokinetic model of vaginally administered dapivirine ring and film formulations.
Br J Clin Pharmacol. 2018 Sep;84(9):1950-1969. doi: 10.1111/bcp.13625. Epub 2018 Jun 19.
4
Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.
Drug Des Devel Ther. 2017 Jun 15;11:1767-1787. doi: 10.2147/DDDT.S133170. eCollection 2017.
5
Simultaneous measurement of etravirine, maraviroc and raltegravir in pigtail macaque plasma, vaginal secretions and vaginal tissue using a LC-MS/MS assay.
J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Jul 1;1025:110-8. doi: 10.1016/j.jchromb.2016.04.048. Epub 2016 May 2.
6
Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.
J Control Release. 2015 Dec 10;219:669-680. doi: 10.1016/j.jconrel.2015.08.042. Epub 2015 Aug 24.
7
Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery.
J Control Release. 2015 Dec 10;219:681-696. doi: 10.1016/j.jconrel.2015.08.018. Epub 2015 Aug 13.
8
The sheep as a model of preclinical safety and pharmacokinetic evaluations of candidate microbicides.
Antimicrob Agents Chemother. 2015 Jul;59(7):3761-70. doi: 10.1128/AAC.04954-14. Epub 2015 Apr 6.
9
Preclinical evaluation of UC781 microbicide vaginal drug delivery.
Drug Deliv Transl Res. 2011 Apr;1(2):175-82. doi: 10.1007/s13346-011-0019-1.
10
Biodistribution and pharmacokinetics of dapivirine-loaded nanoparticles after vaginal delivery in mice.
Pharm Res. 2014 Jul;31(7):1834-45. doi: 10.1007/s11095-013-1287-x. Epub 2014 Jan 22.

本文引用的文献

1
Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers.
J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):154-8. doi: 10.1097/QAI.0b013e31802bb35f.
2
Dawn of non-nucleoside inhibitor-based anti-HIV microbicides.
J Antimicrob Chemother. 2006 Mar;57(3):411-23. doi: 10.1093/jac/dki464. Epub 2006 Jan 23.
4
HIV and sexually transmitted diseases: lethal synergy.
Top HIV Med. 2004 Oct-Nov;12(4):104-7.
5
Recent advances in the development of next generation non-nucleoside reverse transcriptase inhibitors.
Curr Top Med Chem. 2004;4(10):1045-57. doi: 10.2174/1568026043388295.
8
Disruption of the upper female reproductive tract epithelium by nonoxynol-9.
Contraception. 2003 Oct;68(4):273-9. doi: 10.1016/s0010-7824(03)00178-1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验